What is it about?
The benefits of DLBS3233 treatment in subjects with prediabetes
Featured Image
Read the Original
This page is a summary of: Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, Drug Design Development and Therapy, March 2016, Dove Medical Press,
DOI: 10.2147/dddt.s97568.
You can read the full text:
Contributors
The following have contributed to this page